Endocrine Manifestations in Thalassemia Intermedia
DOI:
https://doi.org/10.7439/ijbar.v10i9.5274Keywords:
Thalassemia, beta-globin, Transfusion, Endocrine, Osteopenia, Osteoporosis, Hypothyroidism, Diabetes, IronAbstract
Background: Thalassemia intermedia are genetically similar to thalassemia major with homozygous ?-globin chain defect. Transfusion-independence in such patients is not without side effects. The present study was undertaken to determine the prevalence of endocrine complications in patients of thalassemia intermedia.
Methods: Total 40 patients of thalassemia intermedia were enrolled in the study and divided into 2 groups. Group 1 consist of transfusion dependent (TD) patients (n=24) and group 2 consist of transfusion independent (NTD) patients (n= 16).
Results: Among group 1, commonest endocrine morbidity was short stature (85%), pubertal delay (57.5%), osteopenia (42.5%), osteoporosis (15%), hypothyroidism (15%) and diabetes mellitus (7.5%). While in group 2, short stature (70%), pubertal delay (55%), osteopenia (40%), osteoporosis (22.5%), no case of hypothyroidism and diabetes mellitus. Mean serum ferritin of group 1 was -3562.2 and group 2 was 913.2 and the difference between 2 groups being significant (p=0.0001) indicates that higher iron overload is correlating in group 1 patients having more incidence of endocrine manifestations.
Conclusions: There is significant difference in patients of non-transfusion dependent and transfusion dependent thalassemia intermedia in terms of endocrine manifestations with short stature being the most common manifestation.
Downloads
References
Verlhac S, Morel M, Bernaudin F, B
Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010; 5:11.
Weatherall DJ, Clegg JB, eds. The Thalassaemia Syndromes. 4th ed. Oxford: Blackwell Science; 2001.
Steinberg MH, Forget BG, Higgs DR, Weatherall DJ. Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management; Cambridge University Press: New York, NY, USA, 2009.
Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet 2017.
Saliba AN, Taher AT. Morbidities in non-transfusion-dependent thalassemia. Ann. N. Y. Acad. Sci. 2016; 1368: 82
Cappellini MD, Cohen A, Eleftheriou A et al. Chapter 11 Thalassaemia Intermedia and HbE. Guidelines for the Clinical Management of Thalassaemia [Internet]. 2nd Revised edition. Nicosia (CY): Thalassaemia International Federation; 2008.
Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in
Musallam KM, Sankaran VG, Cappellini MD, Duca L, Nathan DG, Taher AT. Fetal hemoglobin levels and morbidity in untransfused patients with ?-thalassemia intermedia. Blood. 2012; 119:364-367.
Taher AT, Musallam KM, Saliba AN, Garziadei G, Cappellini MD. Hemoglobin level and morbidity in non-transfusion-dependent thalassemia. Blood Cells Mol Dis 2015; 55:108-109.
Soliman AT, De Sanctis V, Kalra S. Anemia and growth. Indian J Endocrinol Metab. 2014; 18 (Suppl 1): S1-5.
Karimi M, Cohan N, De Sanctis V, Mallat NS, Taher A. Guidelines for diagnosis and management of Beta-thalassemia intermedia. Pediatr Hematol Oncol. 2014; 31:583-596.
De Sanctis V, Tangerini A, Testa MR, Lauriola AL, Gamberini MR, Cavallini AR, Rigolin F. Final height and endocrine function in thalassaemia intermedia. J Pediatr Endocrinol Metab. 1998; 11 (Suppl 3): 965-971.
Inati A, Noureldine MA, Mansour A, Abbas HA. Endocrine and bone complications in ?-thalassemia intermedia: current understanding and treatment. Biomed Res Int. 2015; 2015:813098.
Moayeri H and Oloomi Z: Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in beta-thalassemia major. Arch Iran Med 2006; 9:329
Tiosano D, Hochberg Z. Endocrine Complications of Thalassaemia. J Endocrinol Invest. 2001;24(9):716-23.
Saliba AN, Musallam KM, Cappellini MD, et al. Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. Am J Hematol. 2017;92: E35-E37.
Chowdhury P, Saha M, Chowdhury D. Correlation of serum ferritin with hepatic iron overload among non-transfusion dependent beta thalassaemia with haemoglobin E disease patients from Eastern India. J Mol Biomark Diagn.2015; 6: 231.
Taher A, Vichinsky E, Musallam K, Cappellini MD, Viprakasit V. Guidelines for the Management of Non Transfusion Dependent Thalassaemia (NTDT); Thalassemia International Federation: Nicosia, Cyprus, 2013.
Landau H, Matoth I, Landau-Cordova Z, Goldfarb A, Rachmilewitz EA and Glaser B: Cross-sectional and longitudinal study of the pituitary-thyroid axis in patients with thalassaemia major. Clin Endocrinol (Oxf) 1993; 38:55
Agarwal MB, Shah S, Vishwanathan C, Rajadhyaksha G, et al: Thyroid dysfunction in multi-transfused iron loaded thalassemia patients. Indian Pediatr 1992; 29:997
Magro S, Puzzonia P, Consarino C, Galati MC, Morgione S, Porcelli D, Grimaldi S, Tancr
Toumba M, Sergis A, Kanaris C and Skordis N: Endocrine complications in patients with Thalassaemia Major. Pediatr Endocrinol Rev 2007; 5:642
Najafipour F: Evaluation of endocrine disorders in patients with thalassemia major. Int J Endocrinol Metab 2008; 2:104
Al-Akhras A, Badr M, El-Safy U, et al. Impact of genotype on endocrinal complications in ?-thalassemia patients. Biomed Rep. 2016; 4(6):728
Baldini M, Marcon A, Cassin R et al. Beta-Thalassaemia Intermedia: Evaluation of Endocrine and Bone Complications. BioMed Research International, vol. 2014; Article ID 174581:1-5.
Flatau E, Resnitzky P, Kauffman N, Harpaz S, Kohn D. Iron loading and endocrine functions in nontransfused patients with beta-thalassemia intermedia or sickle-cell thalassemia. Isr J Med Sci. 1981;17:22-27.
Taher AT., Musallam KM., Karimi M, El-Beshlawy A, Belhoul K, Daar S, Saned MS, El-Chafic AH, Fasulo MR, Cappellini MD. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the optimal care study. Blood. 2010; 115: 1886-1892.
Downloads
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
How to Cite
